FDA 510(k) Strategy and Submission Support

ConformArc handles the initial enquiry and helps connect you with a relevant provider for this requirement. The selected provider confirms applicability, technical scope, deliverables, fees and timing. The following explains work that may be relevant to the project; it is not a fixed package supplied by ConformArc.

For a medical-device manufacturer entering the US, the first question is which FDA pathway applies to the device and intended use. A 510(k) is a premarket notification for certain devices that demonstrates substantial equivalence to a legally marketed predicate. FDA makes that determination. ConformArc can discuss an introduction to a provider that coordinates a scoped regulatory and evidence review with appropriate specialists before the manufacturer commits to testing or submission.

Build the route around the actual device

The review starts with indications for use, technological characteristics, classification, product code and potential predicate devices. A credible predicate rationale must address meaningful similarities and differences, not simply name a familiar device. From there, the team can map bench, software, electrical safety, EMC, biocompatibility, sterilisation, usability or clinical evidence as applicable. The exact evidence depends on the device and current FDA expectations.

A scoped engagement may deliver a route memo, predicate comparison framework, evidence-gap matrix, test and documentation plan, submission content coordination and support for responses to FDA questions. FDA’s submission formats and guidance should be checked for the actual filing date. ConformArc does not guarantee clearance or act as FDA. A successful 510(k) is clearance, not “FDA approval”; establishment registration and device listing are different obligations.

Start with these records

Provide the device description, intended use, design and risk files, known classification or product code, potential predicates, existing reports, labelling and quality-system status. Quotation should separate consulting, independent testing and FDA fees. The quality-system discussion should reflect FDA’s QMSR, effective 2 February 2026.